Investment Rating - The report initiates coverage with an OUTPERFORM rating for BeiGene [2]. Core Insights - BeiGene is positioned as a leading biopharma company in China, focusing on innovative drug development and global commercialization, with a strong pipeline and significant growth potential [3][11]. - The company is expected to achieve profitability by 2025, driven by the strong performance of its core products, particularly the BTK inhibitor, Zanubrutinib, and the PD-1 inhibitor, Tislelizumab [4][20]. Summary by Sections 1. Innovative Product Globalization - BeiGene has established a robust global presence with over 60 clinical projects and 17 commercialized products, including Zanubrutinib and Tislelizumab, which have been launched in multiple regions [3][11]. - The company aims to become the first biopharma in China to achieve recurring profitability by 2025, supported by its innovative product pipeline and global commercialization capabilities [11][20]. 2. Leadership in Hematology - The combination of BTK inhibitors, BCL-2 inhibitors, and BTK CDAC is expected to solidify BeiGene's leadership in hematological malignancies [5][27]. - Zanubrutinib is projected to double its revenue to $2.6 billion in 2024, further strengthening its market position in the U.S. hematology market [4][20]. 3. Pipeline Development - BeiGene's pipeline focuses on hematological and solid tumors, with several molecules showing best-in-class potential, including Sonrotoclax and BGB-16673 [27]. - The company has a rich pipeline with over 10 early-stage projects expected to report proof-of-concept data in 2025, enhancing its growth prospects [6][27]. 4. Financial Projections and Valuation - Revenue projections for FY25-27 are $5 billion, $6 billion, and $6.7 billion, respectively, with a CAGR of 21% [7]. - The target price is set at HK$182.35, based on a discounted cash flow model with a WACC of 9% and a perpetual growth rate of 4% [7].

Investment Rating - The report initiates coverage with an OUTPERFORM rating for BeiGene [2]. Core Views - BeiGene is positioned as a leading innovator in China's biopharmaceutical sector, with a strong focus on oncology treatments and a robust pipeline of over 60 clinical projects globally [3][11]. - The company is expected to achieve profitability by 2025, driven by significant revenue growth from its core products, particularly the BTK inhibitor, Zanubrutinib, which is projected to double its revenue in 2024 [4][20]. - BeiGene's global commercialization capabilities and a well-established management team are key competitive advantages that will support its growth trajectory [12][29]. Summary by Sections 1. Innovative Product Globalization - BeiGene has a diverse product pipeline and aims to become the first biopharma company to achieve consistent profitability [11]. - The company has 17 commercialized products, including Zanubrutinib and Tislelizumab, with strong sales performance in the US and Europe [20]. - Revenue for 2024 is projected at $3.81 billion, a 55% increase year-over-year, with significant contributions from the US market [20]. 2. Leadership in Hematology - The combination of BTK inhibitors and BCL-2 inhibitors is expected to solidify BeiGene's leadership in hematological malignancies [5]. - Zanubrutinib has shown superior efficacy compared to Ibrutinib, establishing its best-in-class status [5][24]. - The company is also developing Sonratoclax, a BCL-2 inhibitor, which is anticipated to enhance its market position [5]. 3. Expansion in Solid Tumors - BeiGene is actively expanding its presence in solid tumors, with Tislelizumab gaining traction in various indications [11]. - The company is developing next-generation CDK inhibitors targeting a market exceeding $10 billion [11]. - Focus areas include lung cancer and breast cancer, with ongoing clinical trials for multiple candidates [11]. 4. Financial Projections and Valuation - Revenue forecasts for FY25-27 are $5 billion, $6 billion, and $6.7 billion, respectively, with a CAGR of 21% [7]. - The net profit is expected to turn positive by FY25, reaching $390 million by FY26 [7]. - The target price is set at HK$182.35, based on a DCF model with a WACC of 9% and a perpetual growth rate of 4% [7].

Financial Performance - Total revenue for 2024 reached RMB 743.17 million, a year-on-year increase of 5.44%[5] - Net profit attributable to the parent company was RMB -508.84 million, with a net profit excluding non-recurring gains and losses of RMB -554.15 million[5] - Basic earnings per share were RMB -1.23, and the weighted average return on net assets was -53.10%[5] - Operating loss increased by RMB 117.13 million compared to the same period last year, primarily due to increased operating costs and sales expenses[6] Assets and Equity - Total assets at the end of the reporting period were RMB 2,199.93 million, a decrease of 3.81% from the beginning of the year[5] - Equity attributable to the parent company decreased by 41.96% to RMB 703.85 million, with a corresponding decrease in net asset per share to RMB 1.70, down 41.98%[6] Research and Development - R&D expenses amounted to RMB 776.38 million, a 1.01% increase from RMB 768.64 million in the previous year, reflecting the company's commitment to drug development[6] Business Expansion - The company is expanding its overseas supply business for certain products, although revenue growth from these efforts remains limited[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be confirmed in the annual report[8] - Investors are advised to be cautious as the reported net profit and other key indicators may differ from those in the annual report[8]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -420 million and -580 million CNY, indicating an increase in losses compared to the previous year[2]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -465 million and -625 million CNY[2]. - The previous year's net profit attributable to shareholders was -394.53 million CNY, with a total profit of -394.42 million CNY[7]. - The previous year's net profit, excluding non-recurring gains and losses, was -471.83 million CNY[7]. - The company reported a loss per share of -0.95 CNY in the previous year[8]. Revenue Expectations - The estimated operating revenue for 2024 is expected to be between 710 million and 790 million CNY, representing a year-on-year growth of 0.74% to 12.09%[9]. - The increase in revenue is primarily driven by the sustained growth in sales of Adalimumab injection (Gelerit®) and the new overseas supply business of Tocilizumab injection, although the overseas collaboration is still in the early stages[9]. Research and Development - The company has a rich pipeline for drug research and development, with continuous high investment in R&D expenses, contributing to the increase in losses year-on-year[9]. Performance Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this performance forecast as of the announcement date[10]. - The forecast data is preliminary and subject to change pending the audited annual report for 2024[11].

Investment Activities - Investment activities generated a net cash flow of 67.45 million yuan, compared to 140.08 million yuan in the same period last year[34] - Cash inflows from investment activities totaled 904.44 million yuan, a decrease from 1.56 billion yuan in the previous year[34] - Cash outflows from investment activities amounted to 836.99 million yuan, down from 1.42 billion yuan in the prior year[34] - The company invested 740 million yuan in investments, compared to 1.19 billion yuan in the same period last year[34] Financing Activities - Cash inflows from financing activities were 375.05 million yuan, compared to 427.47 million yuan in the same period last year[34] - Cash outflows from financing activities totaled 214.71 million yuan, a significant increase from 30.65 million yuan in the previous year[34] - Net cash flow from financing activities was 160.34 million yuan, down from 396.82 million yuan in the prior year[34] Cash and Cash Equivalents - The net increase in cash and cash equivalents was 142.01 million yuan, compared to 179.04 million yuan in the same period last year[34] - The ending balance of cash and cash equivalents was 256.95 million yuan, down from 322.08 million yuan in the previous year[34] Capital Expenditures - The company spent 96.99 million yuan on the purchase of fixed assets, intangible assets, and other long-term assets, a decrease from 227.88 million yuan in the prior year[34]

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 500 million RMB, representing a 25% growth compared to the same period last year[1]. - The company achieved operating revenue of CNY 402,286,721.86 in the first half of 2024, an increase of 27.85% compared to CNY 314,666,473.81 in the same period last year[16]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2024, representing a 20% year-over-year growth[102]. - The company reported a significant increase in revenue for the first half of 2024, with a year-over-year growth of 25%[106]. - The company reported a net profit margin of 15%, which is an improvement from 12% in the previous year[102]. - The company reported a net loss attributable to shareholders was CNY -236,845,848.07, a reduction in loss of CNY 16,775,025.19 compared to the previous year[18]. - The company reported a net loss for the first half of 2024 was RMB 2,469,094,798.57, compared to a net loss of RMB 2,232,408,924.58 in the same period of 2023, indicating an increase in losses of 10.6%[157]. User Growth and Market Expansion - User data indicates that the active user base has expanded to 1.2 million, reflecting a 30% increase year-over-year[1]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[103]. - Market expansion plans include entering three new international markets by Q3 2024, aiming for a 30% increase in market share[102]. - The company is actively pursuing market expansion strategies, targeting Southeast Asia and Europe for new market entries in 2025[1]. - The company is considering strategic acquisitions to bolster its product offerings, with a target of completing at least two acquisitions by the end of 2024[104]. Research and Development - The company has allocated 15% of its revenue towards R&D, emphasizing its commitment to innovation and new technology development[1]. - The company is investing heavily in R&D, with a budget increase of 25% to enhance technology development and innovation[103]. - Research and development (R&D) expenses amounted to approximately ¥419.91 million, reflecting a decrease of 4.14% compared to the same period last year[47]. - The company has a robust R&D pipeline with 362 R&D personnel, accounting for 30.91% of the total workforce, which is an increase from 28.70% in the previous year[57]. - The company is committed to enhancing its research and development capabilities to support future growth and product launches[27]. Product Development and Pipeline - New product development includes the launch of two innovative drugs, which are expected to enter clinical trials by Q4 2024[1]. - The company is developing multiple innovative drugs and biosimilars targeting major diseases, including cancer and autoimmune diseases[27]. - The company has established partnerships for BAT1706's commercialization in China, Europe, the US, and emerging markets, enhancing market reach[30]. - The company has submitted marketing authorization applications for BAT2206 and has six products in Phase III or pivotal registration studies[27]. - The company aims to adhere to the "Innovation Only for Life" philosophy, focusing on innovative drug development[27]. Financial Stability and Cash Flow - The company has maintained a strong cash position with 200 million RMB in cash reserves, ensuring financial stability for upcoming projects[1]. - The net cash flow from operating activities improved, with a net outflow of CNY -63,260,076.28, a decrease of CNY 155,426,809.31 from the previous year[18]. - The company's cash and cash equivalents increased significantly to RMB 278,358,509.85 from RMB 163,986,759.82, marking a growth of approximately 69.5%[152]. - The company has a total of 362 R&D personnel as of June 30, 2024, accounting for 30.91% of the workforce, including 18 PhD holders and 126 master's degree holders[67]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces significant industry risks due to intense competition in the biopharmaceutical market, which may impact pricing and market share[74]. - The global economic slowdown poses a risk to the company's future business and financial performance, potentially affecting profitability[75]. - The company is at risk of losing key technical personnel, which could delay the development of its in-progress products[72]. Corporate Governance and Compliance - No significant changes in corporate governance or related party transactions were reported during this period[1]. - The management emphasized the importance of adhering to shareholder commitments and regulatory requirements regarding stock transfers[108]. - The company has established various governance rules to protect minority shareholders, but risks remain regarding potential undue influence from major shareholders[76]. - The company has implemented a stock lock-up period for key personnel, lasting 12 months post-IPO[108]. Environmental Responsibility - The company achieved compliance with all pollutant discharge standards, with no exceedances reported during the period[92]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[99]. - The company has established a self-monitoring plan for environmental compliance, with all monitoring results meeting regulatory requirements[98]. Legal Matters - The company reported a significant legal dispute involving a construction contract, with a total amount of 25,346,971.34 RMB frozen until January 11, 2025[133]. - The company faced a lawsuit from Wang Shengwu regarding contract disputes, which was dismissed in April 2024, indicating a favorable outcome for the company[134].

Financial Performance - The net profit attributable to the parent company is expected to be between -220 million and -280 million yuan for the first half of 2024, continuing to incur losses compared to the same period last year [7]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -250 million and -310 million yuan [15]. - The company's operating revenue is expected to increase by 60 million to 90 million yuan compared to the same period last year, driven by market expansion and increased sales of the drug Geleli [12]. - The performance for the first half of 2024 shows no significant changes compared to the same period last year [12]. Sales and Market Expansion - The overseas sales revenue has increased year-on-year following the approval and launch of the drug Tocilizumab injection in the US in May 2024 [12]. Earnings Forecast and Risks - The company confirms that there are no significant uncertainties affecting the accuracy of this earnings forecast [4]. - The earnings forecast has not been audited by a registered accountant [10]. - The company emphasizes the importance of investors being aware of investment risks related to the preliminary earnings data [10]. - The board of directors guarantees the truthfulness, accuracy, and completeness of the announcement content [6]. - The company will provide more accurate financial data in the official 2024 semi-annual report [10].

Financial Data and Key Metrics - The company has already put into production 30,500L capacity, with an additional 36,000L capacity expected to be completed by the end of July [5] - The global biopharmaceutical market is projected to reach approximately $70 billion in the next 5 years, with 60% in the US, 30% in Europe, and 10% in other regions [6] Business Line Data and Key Metrics - TOFIDENCE (tocilizumab injection) and Avzivi® (bevacizumab injection) are being commercialized in Europe and the US, with pricing strategies differing from competitors [3] - BAT8006, a FRα ADC product, has shown superior anti-tumor activity in platinum-resistant ovarian cancer patients with FRα expression levels of TPS≥1% [19] - Betanine® (bevacizumab citrate injection) has shown a 43% risk reduction in clinical studies compared to 16% for similar products [12] Market Data and Key Metrics - The US is the primary market for biologics, with recent FDA and CMS policies favoring the rapid entry of biosimilars into the market [6] - TOFIDENCE began sales in the US in May, with market expansion expected to take time [15] Company Strategy and Industry Competition - The company is preparing to compete in global markets, particularly in the face of potential centralized procurement in China [1][9] - The company is focusing on expanding its production capacity and preparing for market entry of new products [5][12] Management Commentary on Operating Environment and Future Outlook - The company believes that the biopharmaceutical sector will be less affected by US election outcomes, as the focus is more on industries like electric vehicles and electronics [13] - The company is optimistic about the supportive policies for innovative drugs and biopharmaceuticals in China, particularly in Guangzhou [14] Other Important Information - BAT8006 received FDA IND approval in March for Phase II clinical trials in platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [8] - The company is exploring the feasibility of combining BAT8006 with bevacizumab and PD1 for treatment [8] Q&A Session Summary Q1: Impact of potential US tariffs on Chinese goods and company strategy - The company is prepared to compete in centralized procurement scenarios, focusing on production cost competitiveness [1] Q2: Future centralized procurement possibilities for adalimumab and bevacizumab - The company is considering global market competition and preparing for potential centralized procurement [9] Q3: Support measures for innovative drugs in China - The company highlights supportive policies at both national and local levels, particularly in Guangzhou [14] Q4: Sales progress of tocilizumab and bevacizumab in Europe and the US - The company notes that pricing strategies differ from competitors and that market expansion will take time [3][15] Q5: Impact of US-China relations on BD transactions and agreements - The company has not observed any significant impact on BD transactions due to US-China relations [2] Q6: Current and future production capacity - The company has 30,500L capacity in production and expects to complete an additional 36,000L by the end of July [5] Q7: Sales strategy and pricing for tocilizumab and bevacizumab in Europe and the US - The company's partners determine the commercialization strategy, with pricing differing from competitors [3] Q8: Market share in regions outside the US - The company did not provide specific details on market share outside the US [17] Q9: Timeline for biosimilar entry into the US market - It may take six months or more for a biosimilar to enter the US market after approval, with additional time needed to gain market share [20] Q10: Commercialization plans for bevacizumab - The company did not provide specific details on commercialization plans for bevacizumab [4] Q11: Market sales expectations for bevacizumab - The company notes uncertainty in market expectations due to factors like医保准入 [21] Q12: Advantages of FRα ADC and future clinical development plans - BAT8006 has shown superior anti-tumor activity and safety in early data, with plans for further clinical trials [19]

一、获取补助的基本情况 百奥泰生物制药股份有限公司（以下简称"公司"）于 2024 年 1 月 1 日至 本公告披露日，累计获得政府补助款项共人民币 4,141.93 万元，其中，与收益 相关的政府补助为 2,641.93 万元，与资产相关的政府补助为 1,500.00 万元。 二、补助的类型及其对上市公司的影响 公司根据《企业会计准则第 16 号——政府补助》等相关规定，确认上述事 项并划分补助的类型，预计将对公司 2024 年度损益产生积极影响。其中与收益 相关的政府补助为 2,641.93 万元，公司直接计入损益或冲减相关成本费用；与 资产相关的政府补助，计入递延收益。 上述政府补助未经审计，具体的会计处理以及对公司损益的影响最终以审 计机构年度审计确认后的结果为准。敬请广大投资者注意投资风险。 特此公告。 证券代码：688177 证券简称：百奥泰 公告编号：2024-034 百奥泰生物制药股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司董事会 2024 ...

证券代码： 688177 证券简称： 百奥泰 公告编号：2024-032 百奥泰生物制药股份有限公司 自愿披露关于 Avzivi®（贝伐珠单抗注射液）获欧洲 药品管理局人用药品委员会积极意见的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到 了欧洲药品管理局（以下简称"EMA"）的通知，Avzivi®（BAT1706，贝伐珠单 抗注射液）获得EMA人用药品委员会（以下简称"CHMP"）积极意见。CHMP 建议欧盟委员会批准Avzivi®上市，用于治疗转移性结直肠癌、转移性乳腺癌、 非小细胞肺癌、转移性肾细胞癌、上皮性卵巢癌、输卵管癌或原发性腹膜癌、 转移性宫颈癌。 BAT1706（贝伐珠单抗注射液）是百奥泰根据国家药品监督管理局、美国 FDA、欧洲EMA生物类似药相关指导原则开发的贝伐珠单抗注射液。BAT1706 （贝伐珠单抗注射液）是一种人源化单克隆抗体，属于血管内皮生长因子 （VEGF）抑制剂，其通过与VEGF结合，阻断VEGF与其受体的结合，从 ...